FAB — Fusion Antibodies Income Statement
0.000.00%
Last trade - 00:00
- £3.72m
- £3.28m
- £2.90m
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.18 | 3.9 | 4.17 | 4.8 | 2.9 |
Cost of Revenue | |||||
Gross Profit | 0.804 | 1.77 | 2.02 | 2.47 | 0.574 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.69 | 4.95 | 5.41 | 6.12 | 5.76 |
Operating Profit | -1.51 | -1.06 | -1.25 | -1.32 | -2.86 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.5 | -1.07 | -1.26 | -1.33 | -2.86 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.26 | -0.697 | -2.9 | -1.2 | -2.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.26 | -0.697 | -2.9 | -1.2 | -2.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -1.26 | -0.697 | -2.9 | -1.2 | -2.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.057 | -0.032 | -0.114 | -0.046 | -0.1 |